Project-0027. Lay User Usage Study

Pregnancy Clinical Trial

Official title:

Project-0027 Lay User Usage Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02636166
• Other study ID #: PROTOCOL-0772
• Status: Completed
• Phase: N/A
• First received: October 20, 2015
• Last updated: December 16, 2015
• Start date: July 2015
• Est. completion date: December 2015

Study information

• Verified date: October 2015
• Source: SPD Development Company Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study volunteers will be required to conduct a home pregnancy test (HPT) at the trial centre and provide a sample of urine from the same void for further testing.

Volunteers will then complete a product usage questionnaire and leaflet comprehension questionnaire at site.

Follow-up information will be required from all volunteers as both additional urine sample(s) and pregnancy information to establish true pregnancy status at the study visit.

Description:

Eligible volunteers will be recruited into the study and provide informed consent. Volunteers will then test their urine sample with the investigational HPT according to the device Instructions for use and record their result onto the results sheet. A sample of urine from the same void will be obtained for further testing by the study technicians.

The technician will then test the volunteer's sample with a second investigational HPT, a professional use pregnancy test and a Clearblue Digital HPT, the results of which will be used to provide the volunteer with her pregnancy test result. During technician testing, the volunteer will complete the device usability and leaflet comprehension questionnaires.

At the end of the study visit, all volunteers will be provided with materials to allow follow-up for the determination of pregnancy status.

The majority of volunteers will be requested to provide one additional urine sample, collected 2 days after the study visit. If early pregnancy is suspected the volunteer will be requested to provide an additional 7 daily urine samples following the study visit. All volunteers will be required to provide details of pregnancy status (documented menses or pregnancy confirmation by health care professional) after the study visit.

True pregnancy status will be determined by laboratory tests and clinical information. The study will continue until a minimum of 300 pregnant and 300 not pregnant volunteers have completed the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 943
• Est. completion date: December 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female

• Aged 18 or over

• Willing to conduct a personal pregnancy test and reveal their pregnancy status

• Willing to give informed consent

Exclusion Criteria:

• Currently or previously employed by SPD Development Company Ltd. (SPD), Alere, Unipath, Procter and Gamble (P&G), or affiliates.

• Has an immediate relative* currently or previously employed by SPD, Alere, Unipath or P&G or affiliates

• Previously used the investigational HPT within the last six months

• Healthcare professionals (HCP's) with professional experience either using lateral flow based devices or conducting near patient testing

• Confirmed to be pregnant by a healthcare professional and beyond the first trimester

• Taken a hormonal preparation containing human chorionic gonadotropin (hCG) in the last month, e.g. Pregnyl®

Related Conditions & MeSH terms

• Pregnancy

Intervention

Other:
• Clearblue Investigational Pregnancy test
Clearblue Investigational Pregnancy test
• Professional pregnancy test
Alere Professional use pregnancy test
• Clearblue Marketed Pregnancy test
Clearblue Marketed Pregnancy test

Locations

Country	Name	City	State
United Kingdom	Illingworth Research Ltd	Macclesfield	Chester

Sponsors (2)

Lead Sponsor	Collaborator
SPD Development Company Limited	Illingworth Research Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants recording the correct pregnancy test result when testing their own urine sample with the investigational HPT referenced to confirmed pregnancy status	The accuracy of the investigational HPT in volunteer hands compared to pregnancy status	3 months
Secondary	Number of participants recording the same pregnancy test result as a laboratory technician when testing their own urine sample with the investigational HPT.	The agreement between volunteer and technician results using the investigational HPT	3 months
Secondary	Number of participants recording a false positive or false negative pregnancy test result when testing their own urine sample with the investigational HPT referenced to confirmed pregnancy status.	The estimated sensitivity and specificity of the investigational HPT	3 months
Secondary	Calculation of the level of certainty a user can have if the device gives a pregnant (positive predictive value (PPV)) or not pregnant result (Negative predictive value(NPV)).	The estimated NPV and PPV of the investigational HPT	3 months
Secondary	Number of participants correctly answering questions about the product when referencing the instructions for use (IFU) leaflet.	Volunteer leaflet comprehension of the IFU	3 months
Secondary	Participants opinion on using the product.	Volunteer usability of the IFU	3 months